Patient-led campaign organisation Just Treatment has written to the UK Prime Minister Theresa May and Secretary of State for Health and Social Care Matt Hancock calling on the government to...
4 February 2019 News
31 January 2019 Analysis
In this issue: Knock on effects of the Valsartan recall, the future of AI in healthcare, the history of the Petri dish, and much more.
30 January 2019 Comment
Globally, there are 9,052 marketed products for ENT disorders. Most of these pharmaceuticals are small molecules and generics that target G protein-coupled receptors (GPCRs), nuclear receptors, and microbial membranes.
12 February 2018 Comment
GlaxoSmithKline (GSK) is expected to have two of the top-five best-selling drugs in the respiratory market in 2018, maintaining its strong portfolio of products in this market.
20 August 2017
AstraZeneca, along with its global biologics research and development unit MedImmune, and German biotech Ethris have entered a strategic research collaboration to develop stabilised non-immunogenic modified messenger ribonucleic acid (mRNA)...
18 April 2016
GlaxoSmithKline (GSK) has expanded its respiratory medicines production capacity with the opening of a new £56m manufacturing facility in Ware, UK.
3 April 2016
Sandoz Canada has expanded its product range with the introduction of a new respiratory antibiotic, Tobramycin inhalation solution.
16 December 2015
AstraZeneca has entered two agreements in Japan and China as part of its aim to strengthen its operations in these regions to meet growing sales.
3 March 2015
AstraZeneca has completed the acquisition of Actavis's branded respiratory business in the US and Canada for around $600m.